QR Code

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively cor...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Ralph Ja Maas, Janneke S Hoogstad-van Evert, Jolien Mr Van der Meer, Vera Mekers, Somayeh Rezaeifard, Alan J Korman, Paul Kjd de Jonge, Jeannette Cany, Rob Woestenenk, Nicolaas Pm Schaap, Leon F Massuger, Joop H Jansen, Willemijn Hobo, Harry Dolstra
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Taylor & Francis Group 2020-01-01
Rangatū:OncoImmunology
Ngā marau:
ovarian cancer
tigit
dnam-1
cd96
nk cells
checkpoint blockade
Urunga tuihono:http://dx.doi.org/10.1080/2162402X.2020.1843247
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite